Pfizer's Xeljanz meets in Phase III UC trials

Pfizer Inc. (NYSE:PFE) said its twice-daily 10 mg dose of Xeljanz tofacitinib met the primary endpoint in the Phase III OCTAVE Induction 1 and 2 trials to treat ulcerative colitis (UC).

The primary endpoint was measured by the proportion of patients treated with Xeljanz compared to placebo who were in remission at week 8. ...